狄诺塞麦对骨转移有多大的疗效呢？

The trade name Prolia is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density.

On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. In November 2010, denosumab was approved for the prevention of bone-related events in patients and the treatment of solid tumors with bone metastases.

How effective is denosumab on bone metastasis?

In a study analysis, James et al. evaluated the effect of denosumab and zoledronic acid in the treatment of bone-related events in prostate cancer bone metastases, showing that compared with zoledronic acid, denosumab can significantly reduce the risk of bone-related events. A large phase III clinical trial in the United States for patients with newly diagnosed multiple myeloma showed that compared with zoledronic acid, denosumab is not inferior in preventing skeletal-related events and can improve the survival rate of patients, significantly reduce renal toxicity, and has good economic benefits.

Denosumab is the first approved monoclonal antibody specifically targeting RANK ligand. The latest analysis of research presented at the European Society for Medical Oncology (ESMO) Annual Meeting in 2017 showed that among patients who could be surgically resected, 80% improved after receiving neoadjuvant denosumab: 44% underwent surgery with less impact on function, and 37% avoided surgery. In unresectable patients, denosumab resulted in effective long-term disease control, with a 5-year progression-free survival (PFS) rate of 88%.

In summary, the treatment of bone metastasis has a significant effect, greatly improves the patient's quality of life, and provides a new treatment plan for the patient.